


PPF - PMG Global Biotech Fund (I)

February 2025

Investment Style

The fund - with daily liquidity - invests worldwide in biotechnology companies with the aim of achieving medium to long-term capital appreciation. Innovation in biotechnology is the basis for the development of best-in-class / first-in-class drugs with direct benefits for patients. Firms with an innovative drug pipeline generally experience an increase in value and attractiveness to be acquired by larger pharmaceutical companies who want to expand their own pipeline. The investment approach focuses on the mapping of the universe of small and medium-sized biotech companies. Stock selection is based on a bottom-up approach. Depending on market assessments, the fund also invests in established, higher-capitalized biotechnology and pharmaceutical companies. Performance is benchmarked against the NASDAQ Biotechnology Index (NBI).

Performance



The predecessor fund, which implemented the same strategy, increased the NAV from USD 10 to USD 24.97 in the period from March 1997 to June 2009. The graph shows the performance since the launch of today's fund (from June 19, 2009). Source: PMG Fund Management AG | Bloomberg

	MTD	YTD	2024	2023	2022	2021
Fund	-1.37%	+3.97%	-5.37%	-4.55%	-26.67%	-7.40%
NBI	-0.32%	+4.81%	-1.37%	+3.74%	-10.91%	-0.63%


Current Data (28.02.2025)

NAV per Unit	USD 86.10
Fund Assets	USD 16.39 Mio.


Risk/Reward Profile




Allocation by Sector



Allocation by Region



Allocation by Market Capitalization



Top 5 Large Caps

Gilead Sciences	10.12%
Amgen	9.21%
Vertex Pharmaceuticals	8.87%
Regeneron Pharmaceuticals	7.20%
Alnylam Pharma	3.42%

Top 5 Small and Mid Caps

Roivant Sciences	1.68%
Adma Biologics	1.65%
Formycon AG	1.61%
Alkermes	1.49%
Jazz Pharmaceuticals	1.45%

PPF - PMG Global Biotech Fund (I)

Report of the Investment Manager

The hesitant rebound seen in January was not reaffirmed in February. US consumer prices in particular, which rose by 0.5% in January, the largest monthly increase since Aug23, further diminished hopes of forthcoming interest rate cuts. The quarterly results of **Merck** and **Bristol-Myers Squibb**, among others, were received negatively. **L'Oréal**, the largest single shareholder in **Sanoofi**, reduced its stake by around EUR 3 billion. Vaccine sceptic Robert F. Kennedy Jr. was confirmed as Minister of Health. The threat of punitive tariffs against the pharmaceutical industry sounds simple but is in fact extremely complex due to highly globalised production (raw materials, active ingredients, filling and packaging). Moreover, the WTO explicitly exempts pharmaceuticals from punitive tariffs. In the end, the only victim would be the patient (**NBI** Feb -0.32%, YTD +4.81%, **XBI** Feb -4.27%, YTD -1.5%, **S&P 500** Feb -1.42%, YTD +1.24%, **NASDAQ** Feb -3.97%, YTD -2.4%).

Portfolio news:

Some of our heavily weighted stocks fell significantly this month and disappointed across the board:

Formycon (Feb -50.19%, YTD -49.72%) has to make extraordinary write-downs on its biosimilar to Stelara (ustekinumab) in the high double-digit to almost triple-digit, non-cash million Euro range and on FYB201/Cimerli also in the low double-digit million Euro range. There is very strong competition for Stelara biosimilars, leading to a sharp fall in prices. The loss of around EUR 500 in market capitalisation is disproportionate, although the loss of confidence has undoubtedly been severely shaken. In addition, the continuation of the Phase III trial for the biosimilar to Keytruda (pembrolizumab) is no longer necessary following consultation with the FDA. However, discontinuation does not necessarily mean an earlier market launch, especially as the exclusivity protection does not expire until around 2029. Competitors may also be able to skip the Ph3 trial.

Harmony Biosciences (Feb -12.69%, YTD -1.63%) has been facing regulatory headwinds - they received a rejection letter from the FDA on pitolisant for the treatment of excessive daytime sleepiness in adult patients. A Phase 3 pivotal trial for pitolisant is expected to begin in Q425 with a target PDUFA date of 2028.

Illumina (Feb -33.15%, YTD -33.59%) struggled with numerous negative headlines: China puts Illumina on its list of 'unreliable companies' (following the implementation of US tariffs on Chinese products) and the National Institutes of Health (NIH), for its part, cuts support for 'indirect research costs' across the board to 15%, regardless of the rates previously negotiated by a research university or medical centre, by decree of Washington with immediate effect. In addition, a major investor and activist significantly reduced his position. **Grail** (Feb +27.34%, YTD +116.02%) in turn rose significantly due to 'short coverings'.

Also **Incyte's** (Feb -0.89%, YTD +6.41%) Q424 numbers disappointed and Baker Bros. Advisors LLP, Incyte's largest shareholder, is offering 30m shares for divestment.

In addition to another weak **Moderna** (the Trump administration is re-examining the USD 590m contract awarded by the Biden administration to develop a vaccine against bird flu / Feb -21.46%, YTD -25.54%), **Neurocrine Biosciences** (Feb -, YTD -) disappointed with a soft Ingrezza sales forecast, higher costs and raised questions among investors about the company's long-term growth trajectory and existing pipeline.

Regeneron (Feb +3.83%, YTD -1.91%) introduces a dividend (approx. USD 3.52 per year) and increases its share buyback programme by USD 3 bn. **Bio-marin Pharmaceutical** (Feb +12.31%, YTD +8.26 %) and **Krystal Biotech** (Feb +12.21%, YTD +14.42%) Q424 report significantly beat consensus estimates.

Fund Characteristics

Fund Domicile	Luxembourg
Fund Category	UCITS V (FCP)
Legal Registration	CH, DE, LX
Launch Date Share Class	19.06.2009
Fiscal Year End	31.12.
Official Publication	www.swissfunddata.ch
Share Class Distribution Policy	Accumulating
Trading Frequency	daily, till 17:00 (CET)
Settlement	T+1
Subscription Commission	0% (max. 1%)
Redemption Fee	0.25% (in favour of the fund)
Management Fee	1.20%
Performance Fee	20% (subject to High Water Mark and Hurdle Rate)
Benchmark / Hurdle Rate	NASDAQ Biotechnology Index (NBI)
Total Expense Ratio (TER) (2023)	2.12% incl. Performance Fee
Minimum Initial Subscription	USD 5'000
Valor	10173746
ISIN	LU0426487442
WKN	A0RM3H
Bloomberg Code	PMGCPLB LX

Fund Manager, Swiss Representative

PMG Investment Solutions AG
Dammstrasse 23
CH-6300 Zug
Tel. +41 (0)44 215 2838
pmg@pmg.swiss
www.pmg.swiss



Custodian

UBS Europe SE, Luxembourg Branch
5 rue Jean Monnet
L-2180 Luxembourg



Management Company

MultiConcept Fund Management S.A.
5 rue Jean Monnet
L-2180 Luxembourg

Disclaimer: This document is solely intended for advertising and information purposes and is only to be used in distribution activities within Switzerland. Investment in investment funds is subject to market risks. Past performance results are no indication of future results. Especially performance results referring to a period of less than twelve months (Year-to-date-performance, start of investment fund within the last twelve months) are no reliable indicator for future results due to the short comparison period. Issuance and redemption commissions are not included in the performance figures. All figures and information are given without any warranty and errors are reserved. The domicile of the fund is Luxembourg. For interested parties the fund regulations or the articles of incorporation, the "Key Investor Information Documents" and the prospectus in their current versions as well as the annual and semiannual reports are provided free of charge from MultiConcept Fund Management S.A., 5 rue Jean Monnet, L-2180 Luxembourg and from the representative in Switzerland PMG Investment Solutions AG, Dammstrasse 23, 6300 Zug, www.pmg.swiss. Paying agent in Switzerland is InCore Bank AG, Wiesenstrasse 17, CH-8952 Schlieren. Information office and paying agent in Germany is Deutsche Bank A.G., Taunusanlage 12, D-60325 Frankfurt am Main. Information office and paying agent in Austria is Erste Bank der österreichischen Sparkassen AG, Am Belvedere 1, A-1100 Wien. The tax treatment of the funds depends on the personal circumstances of each client and can be subject to future changes. This document is for information only. It does not represent an offer for the purchase or sale of the fund. The fund may not be offered, sold or delivered within the United States.